

1 ***In silico* assessment of immune cross protection between BCoV and**
2 **SARS-CoV-2**

3 Lana Bazan Peters Querne^a, Fernanda Zettel Bastos^a, Mikaela dos Anjos

4 Adur^b, Vitória Cavalheiro^c, Breno Castello Branco Beirão^{b,*}

5 ^a Programa de Pós-graduação em Engenharia de Bioprocessos e Biotecnologia, Universidade
6 Federal do Paraná. Av. Cel. Francisco H. dos Santos, 100, Centro Politécnico, Curitiba, PR,
7 Brazil, CEP 81531-980.

8 ^b Departamento de Patologia Básica, Universidade Federal do Paraná. Av. Cel. Francisco H.
9 dos Santos, 100, Setor de Ciências Biológicas, Curitiba, PR, Brazil, CEP 81531-980.

10 ^c Imunova Análises Biológicas LTDA. R. Imaculada Conceição, 1430, Curitiba, PR, Brazil, CEP
11 80215-182.

12 *Corresponding author: breno.beirao@ufpr.br

13

14 **Abstract**

15 **Background:** Humans have long shared infectious agents with cattle, and the
16 bovine-derived human common cold OC-43 CoV is a not-so-distant example of
17 cross-species viral spill over of coronaviruses. Human exposure to the Bovine
18 Coronavirus (BCoV) is certainly common, as the virus is endemic in most high-
19 density cattle-raising regions. Since BCoVs are phylogenetically close to SARS-
20 CoV-2, it is possible that cross-protection against COVID-19 occurs in people
21 exposed to BCoV.

22 **Methods:** This article shows an *in silico* investigation of human cross-protection
23 to SARS-CoV-2 due to BCoV exposure. We determined HLA recognition and
24 human B lymphocyte reactivity to BCoV epitopes using bioinformatics
25 resources. A retrospective geoepidemiological analysis of COVID-19 was then
26 performed to verify if BCoV/SARS-CoV-2 cross-protection could have occurred
27 in the field. Brazil was used as a model for the epidemiological analysis of the
28 impact of livestock density – as a proxy for human exposure to BCoV – on the
29 prevalence of COVID-19 in people.

30 **Results:** As could be expected from their classification in the same
31 *Betacoronavirus* genus, we show that several human B and T epitopes are
32 shared between BCoV and SARS-CoV-2. This raised the possibility of cross-
33 protection of people from exposure to the bovine coronavirus. Analysis of field
34 data added partial support to the hypothesis of viral cross-immunity from human
35 exposure to BCoV. There was a negative correlation between livestock
36 geographical density and COVID-19. Whole-Brazil data showed areas in the
37 country in which COVID-19 prevalence was disproportionately low (controlled by

38 normalization by transport infrastructure). Areas with high cattle density had
39 lower COVID-19 prevalence in these low-risk areas.

40 **Conclusions:** These data are hypothesis-raising indications that cross-
41 protection is possibly being induced by human exposure to the Bovine
42 Coronavirus.

43

44 **Keywords:** bovine coronavirus (BCoV); cross-reactivity; epitope; *in silico*;
45 epidemiology; SARS-CoV-2.

46 **1. Background**

47 In December 2019 the Severe Acute Respiratory Syndrome Coronavirus
48 2 (SARS-CoV-2) was discovered in Wuhan, in the Chinese province of Hubei
49 (1). SARS-CoV-2 can cause Coronavirus Disease 2019 (COVID-19) and led to
50 a pandemic pneumonia outbreak, declared on March 11, 2020 (2). The
51 symptoms of infected people resemble those of viral pneumonia, such as
52 cough, fever and discomfort when breathing (3). In elderly patients and patients
53 with comorbidities (e.g., diabetes, obesity, and asthma) the development of
54 severe cases with dyspnoea and bilateral pulmonary infiltration is more
55 common, increasing the number of hospitalizations and deaths in this
56 population (4).

57 Coronaviruses are single-stranded RNA viruses belonging to the
58 *Coronaviridae* family, which infects several animal hosts. Within this range of
59 hosts, coronaviruses cause respiratory, gastrointestinal, and neurological
60 diseases. The four genera that compose this family are: *Alphacoronavirus*,
61 *Betacoronavirus*, *Gammacoronavirus* and *Deltacoronavirus* (5,6). Among the
62 Beta-coronaviruses are SARS-CoV-2 and Bovine Coronavirus (BCoV). The
63 latter is responsible for livestock losses, causing diarrhoea in new-born calves
64 and respiratory infections in calves and confined cattle (6,7). The genome of
65 both viruses encodes similar structural proteins: envelope protein (E),
66 membrane protein (M), nucleocapsid protein (N) and spike protein (S); BCoV
67 expresses a hemagglutinin-esterase not present in SARS-CoV-2 (8); viruses
68 also express homologous non-structural proteins (NSP) and open reading
69 frame polyproteins (ORF) (6,9).

70 Cross-reactivity between coronaviruses is known to occur to some extent
71 and might impact on the severity and spread of diseases (10). BCoV and
72 SARS-CoV-2 are aggregated within the same viral genus which illustrates the
73 high structural similarity between them – this is crucial for immune cross-
74 reactivity (11,12). Importantly, there is a history of BCoV spill over to other
75 species, including humans, which seems to have generated at least one of the
76 current human coronaviruses that cause the common cold (8). It is possible that
77 subclinical human infections with BCoV occur routinely, and there is even
78 evidence of BCoV causing clinical signs in susceptible people (13,14).

79 Here, we performed an *in silico* analysis of the correlations between
80 bovine and human coronaviruses. We conducted an immunological assessment
81 of the epitopes of BCoV which may induce protective immune responses in
82 humans against SARS-CoV-2. We searched for peptides originated from BCoV
83 proteins M, N, S and ORF that potentially could induce T and B cell responses
84 in people and that show high identity with SARS-CoV-2. We then used an
85 epidemiological analysis to test the hypothesis that exposure to BCoV induces
86 cross-protection against COVID-19 (cattle density was used as a proxy for
87 BCoV exposure). The results presented here are an indication that BCoV may
88 confer human cross-protection against SARS-CoV-2.

89

90 **2. Methods**

91 *2.1 Peptide setup for immunological assessment*

92 Proteome sequences of Bovine Coronavirus were obtained from the
93 NCBI database and focused on four proteins (Table 1): spike protein (S),

94 membrane protein (M), nucleocapsid protein (N) and replicase polyprotein
95 (Orf1ab). The entire protein sequences were organized in 15-mer peptides that
96 overlapped by 10 amino acids, using a python code (15,16).

97

98 Table 1 – NCBI accession numbers of Bovine Coronavirus and SARS-CoV-2 protein sequences
99 used in the present study.

	Bovine coronavirus	SARS-CoV-2
Spike protein	NP_150077.1	YP_009724390.1
Membrane protein	NP_150082.1	YP_009724393.1
Nucleocapsid protein	NP_150084.1	QQD86936.1
Orf1ab	NP_150073.3	BCT04066.1

100 Orf1ab = replicase polyprotein.

101

102 *2.2 Prediction of T cell reactivity*

103 T cell reactivity of bovine coronavirus peptides was assessed by
104 predicting their binding to human leukocyte antigen class II (HLA II) molecules
105 using IEDB MHC II binding predictions tool (<http://tools.iedb.org/mhcii/>). Peptide
106 binding was predicted to all HLA class II molecules. A 20% percentile rank cut-
107 off was chosen as a universal prediction threshold (16).

108

109 *2.3 Prediction of B cell reactivity*

110 B cell reactivity of bovine coronavirus peptides was assessed using IEDB
111 Bepipred Linear Epitope Prediction 2.0 (<http://tools.iedb.org/bcell/>). The
112 residues with scores above the threshold (0.5) and with 5 amino acids or more
113 were predicted to be part of an epitope (17,18).

114

115 *2.4 Similarity of BCoV peptides in relation to SARS-CoV-2 proteins*

116 All BCoV peptides that were above the thresholds in the analyses of T-
117 and B cells were assessed for their similarity to the corresponding proteins of
118 SARS-CoV-2 (Table 1) using the Multiple Sequence Alignment (Clustal Omega,
119 <https://www.ebi.ac.uk/Tools/msa/clustalo/>). Sequences with an identity greater
120 than or equal to 80% were selected as peptide matches (19).

121

122 *2.5 Epidemiology of COVID-19 and association with BCoV*

123 Spatial correlation between cattle and COVID-19 was assessed using
124 data from Brazil. The country has large and well-defined areas with high cattle
125 density. Also, within-state analyses allow for controlled comparison of COVID-
126 19 risk factors, as the most important public policies that alter COVID-19 risks
127 are more homogeneously distributed in a state level (20).

128 COVID-19 epidemiology was assessed from publicly available data (21).
129 For a within-state analysis, the slope of increase of cases/100,000 people for
130 each city in the Brazilian State of Mato Grosso do Sul (MS) was used (between
131 January, 2020 and September, 2021) (21,22). The slope of COVID-19 cases
132 was compared to the number of cattle/100,000 people for each municipality in
133 the state (23).

134 As a control, the distance from each municipality to the major city in the
135 subregion of the state was compared to the slope of COVID-19 cases (24).
136 General efficiency of public spending (not directly correlated with COVID-19)
137 was also used as a control in a correlation analysis with COVID-19 prevalence.
138 Data from the literature on public investment were used. Spending rigor was
139 scored from 1-4, with four being the best-quality public use of resources (25).

140 The correlation of the data with COVID-19 prevalence was assessed with run's
141 test in a linear correlation.

142 Whole-country data from Brazil was assessed using QGIS 3.24.1 Tisler.
143 COVID-19 data from every Brazilian municipality and the map of Brazilian roads
144 were obtained from the Instituto Brasileiro de Geografia e Estatística (26).
145 Cattle population localization and density was from a previously published
146 dataset (27).

147 COVID-19 prevalence rates, road density and cattle populations were
148 compared by pixel intensity of the respective rasterized layers using 'Point
149 Sampling Tool Plugin' for QGIS (version 0.5.3, by Borys Jurgiel). A grid of dots
150 was layered on top of the maps of interest for analysis using the plugin. The grid
151 was positioned to cover the entirety of Brazilian territory south of the Equator,
152 where cattle-raising regions are located. COVID-19 prevalence was corrected in
153 relation to road density in the respective region. For this, every COVID-19 dot
154 from the analysis grid was divided by the sum of the 9 surrounding road
155 'intensity' dots.

156 Raw data used for epidemiological analysis is provided as a
157 supplementary material.

158 GraphPad Prism 8 (GraphPad Software, Inc., USA) was used for
159 graphing and for statistical analysis. All the data used for this analysis is
160 available as supplementary material.

161

162 **3. Results**

163 *3.1 Peptide setup for immunological assessment*

164 A total of 136, 23, 45 and 709 15-mer peptides that overlapped by 10
165 amino acids were obtained for proteins S, M, N and ORF1ab respectively.

166

167 *3.2 Prediction of T cell reactivity*

168 From the results obtained by the IEDB MHC II binding prediction tool,
169 106 peptides from protein S, 20 peptides from protein M, 24 peptides from
170 protein N and 566 peptides from ORF1ab protein were above the selection
171 threshold. All peptides obtained in this analysis are available as supplementary
172 material.

173

174 *3.3 Prediction of B cell reactivity*

175 From the results obtained by the IEDB Bepipred Linear Epitope
176 Prediction 2.0, 70 peptides from protein S, 9 peptides from protein M, 38
177 peptides from protein N and 386 peptides from ORF1ab protein had scores
178 above the threshold. All peptides obtained in this analysis are available as
179 supplementary material.

180

181 *3.4 Similarity of BCoV peptides in relation to SARS-CoV-2 proteins*

182 Among the peptides that showed good results for putative human T or B
183 cell interactions, only 2 peptides from protein S, 1 peptide from protein M, and 2
184 peptides from protein N showed at least 80% similarity with SARS-CoV-2 (Table
185 2). No peptide sequence from these three proteins was found to be above the
186 cut-off values for both T cells and B cells.

187 Table 2 - Peptides from BCoV spike, membrane and nucleocapsid proteins that were likely to
 188 induce human T- and B cell responses and that showed at least 80% similarity with SARS-CoV-
 189 2.

Peptide	T cell	Similarity (%)	B cell	Similarity (%)
Spike protein				
LEAQAQIDRLINGRL	-	-	QIDRLI	100,0
VDVTNGLGTYVLDLR	-	-	LGTYV	80,0
Membrane protein				
TGSWWSFNPETNNLM	-	-	SFNPETN	100,0
Nucleocapsid protein				
PRWYFYLLGTGPHAK	HLA-DRB5*01:01, HLA-DRB1*04:05, HLA-DRB1*11:01, HLA-DRB1*04:01, HLA-DRB1*01:01, HLA-DQA1*05:01/DQB1*03:01, HLA-DRB1*09:01	86,7	-	-
VLPQGYIEGSGRSA	-	-	YIEGS	80,0

190

191 Regarding the ORF1ab protein, 107 peptides were above the threshold
 192 for potential T- or B cell epitopes. In this case, 28 peptides were found to be
 193 above the cut-off for both T cells and B cells (Table 3).

194

195 Table 3 - Peptides from replicase polyprotein (ORF1ab) that were likely to induce human T- and
 196 B cell responses and that showed at least 80% similarity with SARS-CoV-2. The underlined
 197 BCoV peptide sequence has been reported to induce protective anti-SARS-CoV-2 T cell
 198 responses (28).

Peptide	T cell	Similarity (%)	B cell	Similarity (%)
HYVYIGDPAQLPAPR	HLA-DRB3*01:01, HLA-DRB1*03:01, HLA-DQA1*05:01/DQB1*03:01, HLA-DRB1*13:02, HLA-DRB1*01:01, HLA-DRB1*04:05, HLA-DRB1*04:01	100,0	GDPAQL	100,0
YAISAKNRARTVAGV	HLA-DRB1*11:01, HLA-DRB5*01:01, HLA-DRB1*13:02, HLA-DQA1*01:02/DQB1*06:02, HLA-DQA1*05:01/DQB1*03:01	100,0	AKNRARTV	100,0
DVY <u>LPYPDPSR</u> ILGA	HLA-DRB3*01:01	93,3	YDPDSR	100,0
IERFVSLAIDAYPLV	HLA-DQA1*05:01/DQB1*02:01, HLA-DRB3*01:01, HLA-DRB1*01:01, HLA-DRB4*01:01, HLA-DRB1*03:01, HLA-DRB1*13:02, HLA-DQA1*01:01/DQB1*05:01, HLA-DRB1*07:01, HLA-DRB1*15:01, HLA-DPA1*01:03/DPB1*02:01, HLA-	93,3	SLAIDA	100,0

	DRB1*12:01, HLA-DQA1*03:01/DQB1*03:02, HLA-DPA1*02:01/DPB1*01:01, HLA-DRB1*04:05, HLA-DRB1*04:01, HLA-DRB1*09:01			
KPGGTSSGDATTAFA	HLA-DQA1*05:01/DQB1*03:01, HLA-DRB3*01:01	93,3	TSSGDATT	100,0
LYYQNNVFMSESKCW	HLA-DPA1*02:01/DPB1*01:01, HLA-DPA1*01:03/DPB1*02:01, HLA-DRB1*04:01	93,3	VMSE	100,0
KYTQLCQYLNTTTLA	HLA-DRB1*04:05, HLA-DRB1*04:01, HLA-DRB1*01:01, HLA-DRB1*15:01	93,3	CQYLNT	100,0
YNLWNTFTKLQSLEN	HLA-DQA1*01:02/DQB1*06:02, HLA-DRB1*11:01, HLA-DRB1*08:02, HLA-DRB1*04:05, HLA-DRB1*04:01, HLA-DPA1*01:03/DPB1*02:01, HLA-DPA1*02:01/DPB1*01:01, HLA-DRB5*01:01, HLA-DPA1*03:01/DPB1*04:02, HLA-DRB1*09:01	93,3	FTKLQ	80,0
CSQSDRFYRLANECA	HLA-DRB1*04:05, HLA-DPA1*01:03/DPB1*02:01, HLA-DRB1*01:01, HLA-DRB1*04:01	86,7	DRFYR	80,0
DLKHFFFTQDGNAAI	HLA-DRB3*01:01, HLA-DRB1*01:01, HLA-DRB1*04:05, HLA-DRB1*13:02, HLA-DPA1*01:03/DPB1*02:01, HLA-DRB1*07:01, HLA-DRB1*04:01	86,7	FTQDGN	83,3
KFQTVKPGNFNQDFY	HLA-DRB5*01:01, HLA-DRB1*07:01	86,7	VKPGNFNQ	87,5
LPTLTQMNLKYAISA	HLA-DRB1*09:01, HLA-DQA1*01:02/DQB1*06:02, HLA-DRB1*12:01, HLA-DRB4*01:01	86,7	QMNLKY	100,0
NNGPHEFCSQHTMLV	HLA-DRB1*04:05, HLA-DRB1*07:01, HLA-DRB1*04:01	86,7	FCSQH	100,0
SVINARIRAKHYVYI	HLA-DRB1*13:02, HLA-DRB1*15:01, HLA-DRB1*11:01, HLA-DRB1*12:01, HLA-DRB5*01:01	86,7	IRAKH	80,0
VGILTLDNQLNGKW	HLA-DRB3*01:01, HLA-DRB4*01:01, HLA-DRB1*04:05, HLA-DRB1*03:01	86,7	LDNQLDN	100,0
GSLYV NKHAFHTKPF	HLA-DRB5*01:01	86,7	VNKHAFH	100,0
VVCRFDTRVLNNLNL	HLA-DPA1*03:01/DPB1*04:02, HLA-DRB1*03:01, HLA-DPA1*02:01/DPB1*01:01, HLA-DRB1*15:01	86,7	FDTRVLN	85,7
ACVVCSSQTSRLCGS	HLA-DRB1*03:01, HLA-DQA1*01:02/DQB1*06:02	80,0	CSSQTSRLR	87,5
CIHCANFNILFSMV	HLA-DQA1*01:02/DQB1*06:02, HLA-DPA1*01:03/DPB1*02:01, HLA-DPA1*02:01/DPB1*01:01, HLA-DRB1*15:01, HLA-DRB1*13:02, HLA-DPA1*03:01/DPB1*04:02	80,0	NFNIL	80,0
KGLLKEGSSVDLKHf	HLA-DRB1*04:01, HLA-DRB1*07:01	80,0	KEGSSVD	85,7
NNYDKSAGYPFNKFG	HLA-DRB1*07:01, HLA-DRB3*01:01	80,0	KSAGYPF	85,7
VLGLQTQTVDSAQGS	HLA-DRB1*04:01, HLA-DRB1*01:01, HLA-DRB4*01:01	80,0	TQTVDSA	85,7
WYDFVENPDIINVYK	HLA-DRB3*01:01	80,0	VENPDII	85,7
DMAKFPLKLAGTAVI	HLA-DRB1*01:01, HLA-DRB1*07:01, HLA-DRB1*09:01, HLA-DRB1*08:02, HLA-DRB1*13:02, HLA-DRB1*11:01, HLA-DRB1*04:01, HLA-DRB1*15:01	80,0	PLKLAG	83,3
GTNFPLQLGFSTGID	HLA-DRB1*07:01, HLA-DRB1*09:01, HLA-DRB1*01:01	80,0	QLGFS	100,0

LIISDMYDPITKNIG	HLA-DRB3*01:01, HLA-DRB1*03:01	80,0	DMYDPIT	85,7
MIRDKLALGGSVAIK	HLA-DQA1*05:01/DQB1*03:01, HLA-DRB1*01:01, HLA-DRB1*09:01, HLA-DRB1*07:01, HLA-DRB1*13:02, HLA-DRB1*04:01	80,0	KLALGGS	100,0
PGEQFKHLIPLMTRG	HLA-DRB1*01:01, HLA-DRB1*11:01, HLA-DRB1*04:01, HLA-DRB1*04:05, HLA-DRB1*08:02, HLA-DRB5*01:01, HLA-DRB1*09:01, HLA-DRB4*01:01, HLA-DRB1*12:01, HLA-DPA1*03:01/DPB1*04:02, HLA-DRB1*07:01	80,0	KHLIPL	100,0


199

200

201 *3.5 Epidemiology of COVID-19 and association with BCoV*

202 To test the hypothesis that BCoV exposure may lead to COVID-19 cross-
203 reactive immunity, we performed an epidemiological assessment of the
204 correlation between these factors. We analysed the correlation of COVID-19
205 prevalence to the density of cattle in the Brazilian state of MS. This was
206 performed as an initial investigation into the epidemiological association
207 between human exposure to the Bovine Coronavirus (BCoV) and altered
208 pandemic spread. Cattle density was used as a proxy for BCoV exposure.

209 Cattle density (cattle/100,000 people) negatively correlated with the
210 slope of COVID-19 case increase in MS. In opposition, confounding factors in
211 this epidemiological analysis showed no association with the slope of COVID-19
212 cases in the state (assessed factors were distance of each municipality to the
213 main regional hub city and quality of public spending) (Fig. 1).




214

215 Figure 1 - Linear regression between cattle density and the slope of cumulative COVID-19 case
216 increase in the Brazilian State of Mato Grosso do Sul (MS). Data between Jan/20 and Sep/21
217 were used. Cattle density was calculated as the number of cattle/100,000 people in the
218 municipality. The distance of the municipality to the major hub city was used to control for lower
219 people connectivity of cattle-raising areas. Public spending efficiency was used to control for
220 possible slower responses to the COVID-19 pandemic from cattle-raising municipalities.
221 Analysis by run's test in a linear regression. *P*-values are shown next to each regression. The
222 dotted lines around the linear regression trend indicate the 99% CI.

223

224 In a second proof-of-concept epidemiological analysis, we determined the
225 statistical correlation between a) COVID-19 prevalence throughout the country of
226 Brazil; b) the density of cattle populations in the respective areas. As a normalizer for
227 the data, human circulation was determined by assessing road density in the area.

228 Brazilian municipalities were classified as either a) having less COVID-19 cases
229 than expected by the surrounding road infrastructure or, b) having more COVID-19
230 cases than expected by the surrounding road infrastructure. In the former low-risk
231 cohort, bovine density was negatively correlated to COVID-19 prevalence (Fig. 2).



232

233 Figure 2 – Cattle density was negatively associated to COVID-19 prevalence in Brazil. COVID-
234 19 prevalence (A, in red) and cattle density (B, gray shades) were assessed using a geographic
235 information system. Road density (C) was also assessed as a control for the relevance of
236 human movement in COVID-19 prevalence. Although not shown, the dotted grid applied in (A)
237 was also in (B) and (C) for the respective measurements. The effect of cattle density was
238 assessed separately in areas with low (D) and high risk (E) (as expected from road density).
239 The *P* value indicates departure from linearity for the correlation lines by run's test. The dashed
240 line indicates 95% CI.

241

242 4. Discussion

243 Bovine coronaviruses (BCoV) are members of the *Betacoronavirus*
244 genus along with SARS-CoV-2, denoting their structural similarities. Further,
245 within the *Betacoronavirus*, BCoV is among the most similar viruses to SARS-
246 CoV-2 (29,30). Indeed, cattle can be experimentally infected with SARS-CoV-2
247 (31–33) and bovine coronaviruses have spilled over to humans before - current
248 strains of BCoV can be cultured in human rectal adenocarcinoma cells,

249 demonstrating that cross-species infection is still a risk, if not a common event
250 already (6,34,35). Other works have already discussed the immunological
251 impacts that coronaviruses of domestic animals could have on humans. In
252 Brazil, the use of the *Deltacoronavirus* Avian Infectious Bronchitis is being
253 clinically tested for COVID-19 vaccination, for instance [11, 24].

254 The hypothesis raised here is that BCoV exposure influences human
255 immune responses to COVID-19. We started our evaluation of the cross-
256 protection between BCoV and SARS-CoV by assessing *in silico* if BCoV
257 epitopes could be recognized by human B and T lymphocytes. Here, we report
258 several BCoV epitopes which are likely to be important in the immune response
259 against COVID-19. This analysis is valuable in confirming that infectious
260 exposure to the bovine coronavirus can theoretically induce SARS-CoV-2
261 cross-reactive immune responses – although it must be made clear that human
262 infectivity of BCoV cannot be confirmed with the present analysis.

263 Since BCoV shares epitopes with SARS-CoV-2, it is possible that
264 COVID-19 epidemiology was shaped by human exposure to BCoV, much as
265 smallpox was naturally curtailed by the exposure to cowpox, for instance (36).
266 BCoV naturally and widely occurs in densely populated bovine herds (14) and
267 there is evidence of human transmission (37). In this scenario, BCoV exposure
268 would be one among other interacting factors in COVID-19 spread, such as
269 income and social vulnerability levels (38). The results from the Brazilian state
270 of MS and the wider analysis of the country were supportive of the hypothesis
271 that human exposure to cattle had an impact on the epidemiology of COVID-19.

272 The state of MS was chosen as a proof-of-concept case study, as it is a
273 large beef producer with no megacities, which can “distort” the local
274 epidemiological status due to their large influence on the statistics and due to
275 their disproportionate worldwide connections in relation to other towns (39,40).
276 For Brazil, within-state infrastructure, scholarship, income and animal production
277 conditions are more homogeneous than in inter-state comparisons (41,42), thus
278 explaining the choice of a state for the preliminary epidemiological analysis.

279 COVID-19 data from MS was compared against general efficiency of
280 public spending – an important factor in the spread and control of the pandemic
281 in Brazil (43) – and against distance to major city hubs. Municipalities with more
282 cattle are expected to be further away from regional hubs, since large land
283 areas are needed for extensive bovine farming. Therefore, any association
284 between COVID-19 cases with cattle density could possibly be due to lower
285 connectivity of the municipality, which is a major cause of spatial proliferation of
286 the disease (44). These data were freely available and were therefore used for
287 the analysis of the state of MS. Within MS, cattle density was negatively
288 correlated to COVID-19 cases, being more significant in explaining pandemic
289 expansion than common biases, public spending efficiency and distance to
290 major cities.

291 Whole-country Brazilian COVID-19 data demonstrated an interesting
292 pattern in which some municipalities were more “benefitted” from exposure to
293 cattle. COVID-19 prevalence was corrected for road density, creating an index
294 of cities that had higher or lower COVID-19 prevalence than theoretically
295 expected based on road density (an inference of populational movements,

296 which highly alter infectious disease spread (45,46)). “Lower-than-expected”
297 COVID-19 rates could indicate a myriad of factors, such as better health
298 systems or stricter municipal COVID-19 control laws. In this case, the results
299 would indicate that BCoV exposure only benefited human populations that had
300 low risks for COVID-19. High SARS-CoV-2 exposure may have overcome any
301 benefits conferred by previous contact with BCoV. Regional road density may
302 also not have appropriately normalized COVID-19 prevalence, as it is a single
303 and limited control (47).

304 It must be stressed that it was not the goal of this study to prove the
305 association of BCoV with COVID-19 using epidemiological data. Our analysis is
306 exceedingly restricted for this purpose. Nevertheless, these results are an
307 indication of immune cross-reactivity and potential protection from COVID-19
308 from exposure to BCoV. These data prompt further experimental analyses of
309 the effect of BCoV in people.

310

311 **5. Conclusion**

312 SARS-CoV-2 and BCoV share several common epitopes, which may
313 confer cross-immunity. The relevance of this for the development of the
314 pandemic is yet not known and should be proven with controlled trials of human
315 responses to the bovine virus. Nevertheless, our results for the correlation
316 between COVID-19 prevalence and cattle density are an indication of the role of
317 human exposure to BCoV with regards to the development of the pandemic.

318

319 **List of abbreviations**

320 BCoV, Bovine Coronavirus; MS, Mato Grosso do Sul [State of Brazil];

321

322 **Ethical approval and consent to participate**

323 Not required.

324 **Consent for publication**

325 Not applicable.

326 **Availability of data and materials**

327 All data generated or analysed during this study are included in this published

328 article [and its supplementary information files].

329 **Competing interests**

330 The authors declare that they have no competing interests.

331 **Funding**

332 This work was supported by the Coordenação de Aperfeiçoamento de Pessoal

333 de Nível Superior (CAPES) [grant number 88881.505280/2020-01].

334 **Author contributions**

335 LBPQ and FZB performed the molecular analyses with viral genomic data. VC,

336 MAA and BCBB performed the epidemiological analyses. LBPQ, FZB and

337 BCBB wrote the article. BCBB provided funding for the research.

338 **Acknowledgments**

339 Not applicable.

340

341 References

- 342 1. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure,
343 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 2020
344 Apr 16;181(2):281-292.e6.
- 345 2. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19)
346 Dashboard With Vaccination Data [Internet]. [cited 2023 Jun 25]. Available from:
347 <https://covid19.who.int/>
- 348 3. Chen Y, Li L. SARS-CoV-2: virus dynamics and host response. *Lancet Infect Dis*
349 [Internet]. 2020 May 1 [cited 2023 Jun 25];20(5):515–6. Available from:
350 <https://pubmed.ncbi.nlm.nih.gov/32213336/>
- 351 4. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19.
352 *Nature Reviews Microbiology* 2020 19:3 [Internet]. 2020 Oct 6 [cited 2023 Jun
353 25];19(3):141–54. Available from: [https://www.nature.com/articles/s41579-020-](https://www.nature.com/articles/s41579-020-00459-7)
354 [00459-7](https://www.nature.com/articles/s41579-020-00459-7)
- 355 5. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know.
356 *International Journal of Infectious Diseases* [Internet]. 2020 May 1 [cited 2023
357 Jun 25];94:44. Available from: [/pmc/articles/PMC7102543/](https://pubmed.ncbi.nlm.nih.gov/32213336/)
- 358 6. Vlasova AN, Saif LJ. Bovine Coronavirus and the Associated Diseases. *Front*
359 *Vet Sci*. 2021 Mar 31;8.
- 360 7. Takiuchi E, Alfieri AF, Alfieri AA. Molecular analysis of the bovine coronavirus S1
361 gene by direct sequencing of diarrheic fecal specimens. *Braz J Med Biol Res*
362 [Internet]. 2008 [cited 2023 Jun 25];41(4):277–82. Available from:
363 <https://pubmed.ncbi.nlm.nih.gov/18392449/>
- 364 8. Lang Y, Li W, Li Z, Koerhuis D, Van Den Burg ACS, Rozemuller E, et al.
365 Coronavirus hemagglutinin-esterase and spike proteins coevolve for functional
366 balance and optimal virion avidity. [cited 2023 Jun 25]; Available from:
367 <https://www.pnas.org>
- 368 9. Kung YA, Lee KM, Chiang HJ, Huang SY, Wu CJ, Shih SR. Molecular Virology
369 of SARS-CoV-2 and Related Coronaviruses. *Microbiology and Molecular Biology*
370 *Reviews*. 2022 Jun 15;86(2).
- 371 10. Ellis J, Sniatynski M, Rapin N, Lacoste S, Erickson N, Haines D. SARS
372 coronavirus 2-reactive antibodies in bovine colostrum. *Can Vet J* [Internet]. 2023
373 [cited 2023 Jun 24];337–43. Available from:
374 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031788>
- 375 11. Lee CH, Pinho MP, Buckley PR, Woodhouse IB, Ogg G, Simmons A, et al.
376 Potential CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other
377 coronavirus strains. *Front Immunol*. 2020;11:579480.
- 378 12. What happened to the Covid vaccines Brazil promised to develop? [Internet].
379 [cited 2023 Jul 6]. Available from:
380 <https://brazilian.report/society/2023/06/09/covid-vaccines-promised-develop/>
- 381 13. Virant MJ, Černe D, Petrovec M, Paller T, Toplak I. Genetic characterisation and
382 comparison of three human coronaviruses (Hku1, oc43, 229e) from patients and
383 bovine coronavirus (bcov) from cattle with respiratory disease in Slovenia.
384 *Viruses* [Internet]. 2021 Apr 1 [cited 2023 Jun 25];13(4). Available from:
385 [/pmc/articles/PMC8071153/](https://pubmed.ncbi.nlm.nih.gov/32213336/)

- 386 14. Zhu Q, Li B, Sun D. Advances in Bovine Coronavirus Epidemiology. *Viruses*
387 [Internet]. 2022 May 1 [cited 2023 Jun 25];14(5):1109. Available from:
388 <https://www.mdpi.com/1999-4915/14/5/1109/htm>
- 389 15. Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and
390 Methods for T- and B-Cell Epitope Prediction. *J Immunol Res* [Internet]. 2017
391 [cited 2023 Jul 6];2017. Available from:
392 <https://pubmed.ncbi.nlm.nih.gov/29445754/>
- 393 16. Paul S, Sidney J, Peters B, Sette A. Development and validation of a broad
394 scheme for prediction of HLA class II restricted T cell epitopes. In: *Proceedings*
395 *of the 5th ACM Conference on Bioinformatics, Computational Biology, and*
396 *Health Informatics*. 2014. p. 733–8.
- 397 17. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al.
398 Protein identification and analysis tools on the ExPASy server. Springer; 2005.
- 399 18. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving
400 sequence-based B-cell epitope prediction using conformational epitopes. *Nucleic*
401 *Acids Res* [Internet]. 2017 Jul 3 [cited 2023 Jul 6];45(W1):W24–9. Available
402 from: <https://dx.doi.org/10.1093/nar/gkx346>
- 403 19. Reche PA. Potential cross-reactive immunity to SARS-CoV-2 from common
404 human pathogens and vaccines. *Front Immunol*. 2020;2694.
- 405 20. Informações básicas municipais [Internet]. [cited 2023 Jun 25]. Available from:
406 http://tabnet.fiocruz.br/dhx.exe?observatorio/fat_indicadores.def
- 407 21. Covid19 por Município - Brasil.IO [Internet]. [cited 2023 Jul 6]. Available from:
408 <https://brasil.io/covid19/>
- 409 22. Islam ARMT, Hasanuzzaman M, Shammi M, Salam R, Bodrud-Doza M, Rahman
410 MM, et al. Are meteorological factors enhancing COVID-19 transmission in
411 Bangladesh? Novel findings from a compound Poisson generalized linear
412 modeling approach. *Environmental Science and Pollution Research*.
413 2021;28:11245–58.
- 414 23. Pesquisa da Pecuária Municipal | IBGE [Internet]. [cited 2023 Jul 6]. Available
415 from: <https://www.ibge.gov.br/estatisticas/economicas/agricultura-e-pecuaria/9107-producao-da-pecuaria-municipal.html>
- 416 24. Estudo da Dimensão Territorial do Estado de MS: Regiões de Planejamento –
417 SEMADESC [Internet]. [cited 2023 Jul 6]. Available from:
418 [https://www.semadesc.ms.gov.br/estudo-da-dimensao-territorial-do-estado-de-](https://www.semadesc.ms.gov.br/estudo-da-dimensao-territorial-do-estado-de-ms-regioes-de-planejamento/)
419 [ms-regioes-de-planejamento/](https://www.semadesc.ms.gov.br/estudo-da-dimensao-territorial-do-estado-de-ms-regioes-de-planejamento/)
- 420 25. Dorsa ACC, Taveira JC, Pereira MS, Santos FK, Costa RB. Eficiência dos
421 municípios de Mato Grosso do Sul: uma abordagem baseada em fronteira
422 determinística. *Interações (Campo Grande)*. 2020;21:663–80.
- 423 26. Portal de mapas do IBGE [Internet]. [cited 2022 Apr 15]. Available from:
424 <https://portaldemapas.ibge.gov.br/portal.php#homepage>
- 425 27. Gilbert M, Nicolas G, Cinardi G, Van Boeckel TP, Vanwambeke SO, Wint GRW,
426 et al. Global distribution data for cattle, buffaloes, horses, sheep, goats, pigs,
427 chickens and ducks in 2010. *Sci Data*. 2018;5.
- 428 28. Swaminathan S, Lineburg KE, Ambalathingal GR, Crooks P, Grant EJ, Mohan S
429 V., et al. Limited Recognition of Highly Conserved Regions of SARS-CoV-2.
430

- 431 Microbiol Spectr [Internet]. 2022 Feb 23 [cited 2023 Jun 25];10(1). Available
432 from: <https://journals.asm.org/doi/10.1128/spectrum.02780-21>
- 433 29. Zhou H, Ji J, Chen X, Bi Y, Li J, Wang Q, et al. Identification of novel bat
434 coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and
435 related viruses. *Cell* [Internet]. 2021 Aug 19 [cited 2023 Jul 6];184(17):4380-
436 4391.e14. Available from: <https://pubmed.ncbi.nlm.nih.gov/34147139/>
- 437 30. Tilocca B, Soggiu A, Musella V, Britti D, Sanguinetti M, Urbani A, et al. Molecular
438 basis of COVID-19 relationships in different species: a one health perspective.
439 *Microbes Infect*. 2020 May 1;22(4–5):218–20.
- 440 31. Ulrich L, Wernike K, Hoffmann D, Mettenleiter TC, Beer M. Experimental
441 Infection of Cattle with SARS-CoV-2. *Emerg Infect Dis* [Internet]. 2020 Dec 1
442 [cited 2023 Jul 6];26(12):2979–81. Available from:
443 <https://pubmed.ncbi.nlm.nih.gov/33034284/>
- 444 32. Fusco G, Cardillo L, Levante M, Brandi S, Picazio G, Napoletano M, et al. First
445 serological evidence of SARS-CoV-2 natural infection in small ruminants: Brief
446 report. *Vet Res Commun*. 2023;
- 447 33. Bosco-Lauth AM, Walker A, Guilbert L, Porter S, Hartwig A, McVicker E, et al.
448 Susceptibility of livestock to SARS-CoV-2 infection. *Emerg Microbes Infect*.
449 2021;10(1):2199–201.
- 450 34. Brüssow H, Brüssow L. Clinical evidence that the pandemic from 1889 to 1891
451 commonly called the Russian flu might have been an earlier coronavirus
452 pandemic. *Microb Biotechnol* [Internet]. 2021 Sep 1 [cited 2023 Jul
453 6];14(5):1860–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/34254725/>
- 454 35. Stipp DT. Detecção do coronavírus bovino em episódios de diarreia neonatal em
455 rebanhos bovinos brasileiros. 2007;
- 456 36. Riedel S. Edward Jenner and the history of smallpox and vaccination. *Proc (Bayl
457 Univ Med Cent)* [Internet]. 2005 Jan 1 [cited 2023 Jul 6];18(1):21. Available from:
458 </pmc/articles/PMC1200696/>
- 459 37. Zhu Q, Li B, Sun D. Advances in Bovine Coronavirus Epidemiology. *Viruses*
460 [Internet]. 2022 May 1 [cited 2023 Jun 25];14(5). Available from:
461 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147158>
- 462 38. Cestari VRF, Florêncio RS, Sousa GJB, Garces TS, Maranhão TA, Castro RR,
463 et al. Social vulnerability and COVID-19 incidence in a Brazilian metropolis. *Cien
464 Saude Colet* [Internet]. 2021 Mar 1 [cited 2023 Jul 6];26(3):1023–33. Available
465 from: <https://pubmed.ncbi.nlm.nih.gov/33729356/>
- 466 39. Ren H, Zhao L, Zhang A, Song L, Liao Y, Lu W, et al. Early forecasting of the
467 potential risk zones of COVID-19 in China's megacities. *Science of the Total
468 Environment*. 2020 Aug 10;729.
- 469 40. Urban densities and the Covid-19 pandemic: Upending the sustainability myth of
470 global megacities | ORF [Internet]. [cited 2023 Jul 6]. Available from:
471 [https://www.orfonline.org/research/urban-densities-and-the-covid-19-pandemic-
472 upending-the-sustainability-myth-of-global-megacities-65606/](https://www.orfonline.org/research/urban-densities-and-the-covid-19-pandemic-upending-the-sustainability-myth-of-global-megacities-65606/)
- 473 41. Lebioda L, Cabral GO, Tezza R. A Homogeneidade da Inclusão Digital no Brasil:
474 Sonho ou Realidade? *Revista Informação na Sociedade Contemporânea*
475 [Internet]. 2019 Dec 30 [cited 2023 Jul 6];3(1):1–18. Available from:
476 <https://periodicos.ufrn.br/informacao/article/view/19118>

- 477 42. Krawczyk NR, Vieira VL. Homogeneidade e heterogeneidade nos sistemas
478 educacionais: Argentina, Brasil, Chile e México. *Cadernos de Pesquisa*
479 [Internet]. 2006 Sep [cited 2023 Jul 6];36(129):673–704. Available from:
480 <https://www.scielo.br/j/cp/a/VJN8jzhCtnBpkkyMPs4qD6y/?lang=pt>
- 481 43. Szylovec A, Umbelino-Walker I, Cain BN, Ng HT, Flahault A, Rozanova L.
482 Brazil's Actions and Reactions in the Fight Against COVID-19 from January to
483 March 2020. *Int J Environ Res Public Health* [Internet]. 2021 Jan 2 [cited 2023
484 Jul 6];18(2):1–16. Available from: <https://pubmed.ncbi.nlm.nih.gov/33440812/>
- 485 44. Jo Y, Hong A, Sung H. Density or Connectivity: What Are the Main Causes of
486 the Spatial Proliferation of COVID-19 in Korea? *Int J Environ Res Public Health*
487 [Internet]. 2021 May 2 [cited 2023 Jul 6];18(10). Available from:
488 <https://pubmed.ncbi.nlm.nih.gov/34065031/>
- 489 45. Khavarian-Garmsir AR, Sharifi A, Moradpour N. Are high-density districts more
490 vulnerable to the COVID-19 pandemic? *Sustain Cities Soc*. 2021 Jul
491 1;70:102911.
- 492 46. Guan C, Tan J, Hall B, Liu C, Li Y, Cai Z. The Effect of the Built Environment on
493 the COVID-19 Pandemic at the Initial Stage: A County-Level Study of the USA.
494 *Sustainability (Switzerland)* [Internet]. 2022 Mar 1 [cited 2023 Jun
495 25];14(6):3417. Available from: <https://www.mdpi.com/2071-1050/14/6/3417/htm>
- 496 47. Coura-Vital W, Cardoso DT, Ker FT de O, Magalhães FDC, Bezerra JMT,
497 Viegas AM, et al. Spatiotemporal dynamics and risk estimates of COVID-19
498 epidemic in Minas Gerais State: analysis of an expanding process. *Rev Inst Med*
499 *Trop Sao Paulo* [Internet]. 2021 Mar 24 [cited 2022 Apr 15];63. Available from:
500 <http://www.scielo.br/j/rimtsp/a/yfqPmQ5SyDCscbmy7gbhFsD/?lang=en>
501
- 502

